DPP-1 Inhibitors Aim to Reduce Bronchiectasis Flare-Ups
A new class of drugs offers a disease-based approach to managing non-cystic fibrosis bronchiectasis by targeting airway inflammation.
Tag: brensocatib Brinsupri
DPP-1 Inhibitors Aim to Reduce Bronchiectasis Flare-Ups
A new class of drugs offers a disease-based approach to managing non-cystic fibrosis bronchiectasis by targeting airway inflammation.
Read More
Brensocatib Reduced Bronchiectasis Exacerbations, Improved Symptoms in Asian Patients
The phase 3 ASPEN trial revealed brensocatib 10 mg and 25 mg significantly reduced bronchiectasis exacerbations, prolonged time to first exacerbation, and improved quality-of-life scores.
Read More